Entero Therapeutics, Inc. (ENTO)
NASDAQ: ENTO · Real-Time Price · USD
0.4898
-0.0094 (-1.88%)
Mar 31, 2025, 3:26 PM EDT - Market open
Entero Therapeutics Employees
Entero Therapeutics had 9 employees as of December 31, 2023. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,127,763
Market Cap
2.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ENTO News
- 6 days ago - Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Newsfile Corp
- 6 weeks ago - Entero Therapeutics Appoints Richard Paolone as CEO - GlobeNewsWire
- 7 weeks ago - Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members - GlobeNewsWire
- 4 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 4 months ago - ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO - Business Wire
- 4 months ago - Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company - GlobeNewsWire
- 6 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire
- 7 months ago - Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - GlobeNewsWire